Title : Pharmacological properties of bexagliflozin, a novel sodium-glucose cotransporter-2 (SGLT2) Inhibitor
Diabetes mellitus represents a large-scale health concern and has become a distressing hazard in the modern epoch of compromised lifestyles. So, there is an imperative need for screening and developing new pharmacologically active compounds that can meet still existing insufficiency of the present antidiabetic agents. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are relatively novel glucose-lowering drugs that additionally promote weight loss and the reduction of blood pressure. Moreover, the data from pioneering trials consistently demonstrated that the beneficial effects of SGLT2 inhibitors extended to non-diabetic patients with chronic kidney disease and/or heart failure with reduced ejection fraction. This is not a surprise since the kidney plays a vital role in assuring glucose homeostasis, gluconeogenesis, and the reabsorption of filtered glucose in the proximal tubules. Accordingly, the SGLT2 present in the proximal tubule is actually responsible for glucose reabsorption. Bexagliflozin is a recently registered and novel SGLT2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Unfortunately, it is not recommended in patients with type 1 diabetes mellitus since it may increase the risk of diabetic ketoacidosis. Given the previous facts, the main objectives of this presentation will be to clarify the pharmacological properties of bexagliflozin, including pharmacodynamics, pharmacokinetics, indications, and contraindications for use, adverse drug reactions, as well as the most important drug interactions. This will provide a better understanding of this new-in-pharmacotherapy drug for type 2 diabetes mellitus, thus helping clinicians in appropriate prescribing and its adequate clinical use.